UBS Maintains Neutral on Asbury Automotive Group, Lowers Price Target to $193
UBS analyst Joseph Spak maintains Asbury Automotive Group (NYSE:ABG) with a Neutral and lowers the price target from $250 to $193.
Stocks · News reference
Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday
U.S. stocks mixed; Dow up ~200 points. Penske Automotive surged on a $16.3B go-private deal, while OPKO, Ericsson and others rallied.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JP Morgan Maintains Underweight on Asbury Automotive Group, Lowers Price Target to $185
JP Morgan analyst Rajat Gupta maintains Asbury Automotive Group (NYSE:ABG) with a Underweight and lowers the price target from $190 to $185.
Barclays Maintains Equal-Weight on Asbury Automotive Group, Lowers Price Target to $230
Barclays analyst John Babcock maintains Asbury Automotive Group (NYSE:ABG) with a Equal-Weight and lowers the price target from $265 to $230.
Adlai Nortye Group shares are trading higher after the company announced clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA, Darmstadt, Germany for the anti-EGFR antibody cetuximab.
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
Adlai Nortye announced clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA, Darmstadt, Germany to evaluate AN4035, a first-in-class pan-RAS(ON) inhibitor-based ADC, in combination with cetuximab in an ongoing global Phase I trial for CEACAM5-enriched RAS-addicted solid tumors. Both companies will supply cetuximab at no cost for their respective trial sites.
Adlai Nortye Group enters Clinical Trial Collaboration And Supply Agreements With Eli Lilly And Merck KGaA For The ERBITUX Anti-EGFR Antibody
These agreements will support Adlai Nortye’s ongoing Phase I trial evaluating AN4035, a pan-RAS(ON) inhibitor-based ADC, both as monotherapy and in combination with cetuximab, in CEACAM5-enriched RAS-addicted solid